Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF

AstraZeneca PLC (AZN)

Create Alert
Create Alert
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile






Delivery Method


Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
119.450 +1.500    +1.27%
11:35:37 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 19,264
  • Bid/Ask: 118.550 / 120.250
  • Day's Range: 118.500 - 119.900
Type:  Equity
Market:  Germany
ISIN:  GB0009895292 
WKN:  886455
AstraZeneca 119.450 +1.500 +1.27%

Astrazeneca PLC Company Profile

Get an in-depth profile of AstraZeneca PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.


Equity Type


AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Contact Information

Address 1 Francis Crick Avenue Cambridge Biomedical Campus
Cambridge, CB2 0AA
United Kingdom
Phone 44 20 3749 5000
Fax -

Top Executives

Name Age Since Title
Pascal Soriot 62 2012 CEO & Executive Director
Philip Arthur John Broadley 62 2017 Senior Independent Non-Executive Director
Marcus Wallenberg 67 1999 Non-Executive Director
Deborah DiSanzo Eldracher 63 2017 Independent Non-Executive Director
Shu Kam Mok 61 2019 Independent Non-Executive Director
Nazneen Rahman 55 2017 Independent Non-Executive Director
Rain Henderson - - Member of External Sustainability Advisory Board
Diana Layfield 51 2020 Independent Non-Executive Director
Sherilyn S. D. McCoy 64 2017 Independent Non-Executive Director
Pankaj Bhatia - - Member of External Sustainability Advisory Board
Michel Demare 67 2019 Independent Chairman
Polly Courtice 71 - Member of External Sustainability Advisory Board
Louise Nicholls - - Member of External Sustainability Advisory Board
Euan A. Ashley 51 2020 Independent Non-Executive Director
Andreas Rummelt 67 2021 Independent Non-Executive Director
Anna Olive Magdelene Manz 50 2023 Non-Executive Director
Jeffrey Pott - 2009 CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Pam P. Cheng 52 2015 EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Menelas Pangalos 56 2013 EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Aradhana Sarin 48 2021 CFO & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

AZN Comments

Write your thoughts about Astrazeneca PLC
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oct 28, 2021 0:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Double top in reach
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email